


Pharmaceutical Cost Reports

Fully Insured Individual and Group Coverage
(Excludes self-funded insured health groups)


2021 Q1 – Q4 RX Summary by Generic, Brand, and Over the Counter

| Brand Type | Rx Count | Percent of Claims | Allowed Amt | % Of Dollar Value |
|------------|--------------|-------------------|-------------------|-------------------|
| Brand | 1,560,813 | 24.17 | \$ 804,539,813.86 | 87.13 |
| Generic | 4,843,950 | 75.00 | \$ 114,779,871.99 | 12.43 |
| OTC | 53,498 | 0.83 | \$ 4,068,311.26 | 0.44 |
| Total | 6,458,261.00 | | \$ 923,387,997.11 | |

Percent of Claims



Percent of Dollar Value



2021 Q1 – Q4 Top 10 Drug Categories

| Drug Categories | Charged | Allowed | Paid | Member Responsibility |
|-------------------------------|-------------------|------------------|------------------|-----------------------|
| Analgesics | \$ 35,119,332.82 | \$ 12,818,071.75 | \$ 10,385,900.81 | \$ 2,375,362.14 |
| Anticoagulants | \$ 21,397,332.27 | \$ 16,200,406.68 | \$ 13,528,674.04 | \$ 2,669,233.94 |
| Antidiabetic agents | \$ 115,777,468.99 | \$ 86,663,577.88 | \$ 76,553,221.11 | \$ 10,029,156.45 |
| Antineoplastics | \$ 58,833,189.53 | \$ 34,956,902.06 | \$ 33,675,569.09 | \$ 1,065,581.60 |
| Bronchodilators | \$ 24,432,630.26 | \$ 18,014,005.45 | \$ 15,129,375.14 | \$ 2,871,346.62 |
| Central Nervous System Agents | \$ 29,554,595.85 | \$ 19,173,420.41 | \$ 14,851,457.40 | \$ 4,292,793.20 |
| Hormones/Hormone modifiers | \$ 39,097,907.28 | \$ 26,771,654.97 | \$ 23,522,699.00 | \$ 3,203,597.57 |
| Immunostimulants | \$ 17,939,168.62 | \$ 13,479,486.04 | \$ 12,770,042.97 | \$ 523,042.36 |
| Immunosuppressive agents | \$ 122,225,645.60 | \$ 90,617,908.77 | \$ 86,355,957.73 | \$ 3,477,145.22 |
| Sex Hormones | \$ 22,766,842.29 | \$ 14,404,541.50 | \$ 11,024,703.29 | \$ 3,346,392.52 |

2021 Q1 – Q4 Top 30 Drugs by Average Dollar Volume *

| Trade Name | RX Type | Average Day Supply | Average Charged | Average Allowed | Average Paid | Average Member Responsibility |
|--|---------|--------------------|-----------------|-----------------|--------------|-------------------------------|
| HAEGARDA C1 ESTERASE INHIBITOR SUBCUTANEOUS HUMAN | Brand | 28 | \$ 86,898.29 | \$ 57,269.03 | \$ 56,732.68 | \$ 167.93 |
| TAKHZYRO | Brand | 28 | \$ 80,130.34 | \$ 47,048.76 | \$ 46,695.54 | \$ 353.22 |
| KORLYM | Brand | 30 | \$ 43,852.92 | \$ 43,852.92 | \$ 43,557.85 | \$ 295.07 |
| ADVATE | Brand | 26 | \$ 85,786.60 | \$ 36,865.97 | \$ 36,593.39 | \$ 226.77 |
| OCREVUS | Brand | 0 | \$ 109,176.70 | \$ 32,400.73 | \$ 31,920.34 | \$ 480.39 |
| HEMLIBRA | Brand | 27 | \$ 51,409.21 | \$ 30,603.25 | \$ 30,375.46 | \$ 99.09 |
| FIRAZYR | Brand | 11 | \$ 41,003.40 | \$ 33,476.40 | \$ 28,785.10 | \$ 4,691.30 |
| ORENITRAM | Brand | 30 | \$ 45,901.80 | \$ 25,727.04 | \$ 25,641.33 | \$ 85.71 |
| TRIKAFTA | Brand | 27 | \$ 29,311.11 | \$ 24,552.81 | \$ 24,283.52 | \$ 256.26 |
| KALYDECO | Brand | 28 | \$ 27,872.75 | \$ 23,419.22 | \$ 23,251.39 | \$ 167.84 |
| EPCLUSA | Brand | 28 | \$ 29,279.98 | \$ 23,314.66 | \$ 22,837.53 | \$ 477.13 |
| SYMDEKO | Brand | 28 | \$ 28,928.94 | \$ 22,250.91 | \$ 22,101.28 | \$ 94.79 |
| YERVOY | Brand | 0 | \$ 44,341.42 | \$ 20,864.01 | \$ 20,864.01 | \$ 0.00 |
| ORKAMBI | Brand | 28 | \$ 25,103.08 | \$ 20,976.21 | \$ 20,818.11 | \$ 47.94 |
| STELARA | Brand | 38 | \$ 26,354.47 | \$ 21,307.81 | \$ 20,696.82 | \$ 339.47 |

| | | | | | | |
|-----------|-------|----|--------------|--------------|--------------|-------------|
| RETEVMO | Brand | 30 | \$ 26,667.63 | \$ 20,649.06 | \$ 20,649.06 | \$ 0.00 |
| VYNDAMAX | Brand | 24 | \$ 24,694.75 | \$ 20,403.69 | \$ 20,301.06 | \$ 102.63 |
| ICLUSIG | Brand | 30 | \$ 60,137.30 | \$ 20,282.42 | \$ 20,115.94 | \$ 166.48 |
| TUKYSA | Brand | 30 | \$ 27,545.06 | \$ 20,120.96 | \$ 20,107.82 | \$ 13.14 |
| UPTRAVI | Brand | 30 | \$ 34,428.38 | \$ 19,466.02 | \$ 19,447.27 | \$ 18.75 |
| TYVASO | Brand | 28 | \$ 28,422.49 | \$ 19,225.04 | \$ 19,118.14 | \$ 76.38 |
| CABOMETYX | Brand | 24 | \$ 22,529.02 | \$ 18,865.83 | \$ 18,865.59 | \$ 0.24 |
| PALYNZIQ | Brand | 28 | \$ 22,262.38 | \$ 19,104.34 | \$ 18,681.55 | \$ 422.79 |
| REMODULIN | Brand | 19 | \$ 43,424.05 | \$ 22,026.04 | \$ 17,792.84 | \$ 4,233.21 |
| POMALYST | Brand | 27 | \$ 22,204.14 | \$ 17,790.38 | \$ 17,679.66 | \$ 81.05 |
| SKYRIZI | Brand | 45 | \$ 21,013.73 | \$ 17,641.75 | \$ 16,999.74 | \$ 519.99 |
| KUVAN | Brand | 30 | \$ 20,419.27 | \$ 17,717.16 | \$ 16,696.93 | \$ 529.00 |
| REVLIMID | Brand | 26 | \$ 20,870.20 | \$ 16,846.59 | \$ 16,437.95 | \$ 291.44 |
| RUBRACA | Brand | 30 | \$ 29,161.93 | \$ 16,773.48 | \$ 15,753.47 | \$ 693.78 |
| JYNARQUE | Brand | 27 | \$ 19,448.77 | \$ 15,667.15 | \$ 15,492.98 | \$ 184.24 |

2021 Q1 – Q4 Top 30 Drugs by Total Dollar Volume *

| Trade Name | RX Type | Total Charged | Total Allowed | Total Paid | Total Member Responsibility |
|----------------------|---------|-------------------|------------------|------------------|-----------------------------|
| HUMIRA | BRAND | \$ 102,848,535.59 | \$ 82,880,283.16 | \$ 78,405,614.70 | \$ 3,789,589.26 |
| STELARA | BRAND | \$ 47,279,914.04 | \$ 38,226,207.67 | \$ 37,130,086.85 | \$ 609,011.51 |
| ATORVASTATIN CALCIUM | GENERIC | \$ 28,872,353.51 | \$ 1,450,317.96 | \$ 504,738.80 | \$ 945,650.26 |
| OZEMPIC | BRAND | \$ 26,001,972.42 | \$ 20,623,894.89 | \$ 18,803,626.45 | \$ 1,807,554.99 |
| ENBREL | BRAND | \$ 24,587,071.47 | \$ 20,075,097.47 | \$ 18,782,367.80 | \$ 1,207,571.75 |
| TRULICITY | BRAND | \$ 21,464,387.20 | \$ 16,588,525.65 | \$ 14,943,397.15 | \$ 1,644,696.03 |
| NORDITROPIN | BRAND | \$ 20,350,329.14 | \$ 15,810,209.05 | \$ 15,169,671.17 | \$ 603,494.42 |
| TRIKAFTA | BRAND | \$ 19,110,844.08 | \$ 16,008,432.63 | \$ 15,832,855.68 | \$ 167,084.23 |
| VYVANSE | BRAND | \$ 17,434,449.89 | \$ 13,811,122.16 | \$ 10,762,374.83 | \$ 3,027,337.81 |
| DUPIXENT | BRAND | \$ 16,262,077.64 | 4 13,241,669.35 | \$ 11,588,695.76 | \$ 1,394,602.01 |
| ARIPIPRAZOLE | GENERIC | \$ 15,930,636.53 | \$ 425,446.64 | \$ 218,903.27 | \$ 206,757.99 |
| OTEZLA | BRAND | \$ 15,725,219.93 | \$ 12,966,123.42 | \$ 11,563,176.52 | \$ 1,080,629.13 |
| COSENTYX | BRAND | \$ 15,661,352.58 | \$ 12,594,966.43 | \$ 11,731,505.58 | \$ 716,105.07 |
| ROSUVASTATIN CALCIUM | GENERIC | \$ 15,248,354.98 | \$ 632,348.80 | \$ 278,390.62 | \$ 353,992.61 |
| OMEPRAZOLE | GENERIC | \$ 15,229,535.33 | \$ 719,903.03 | \$ 115,070.98 | \$ 604,294.64 |

| | | | | | |
|-----------------------------|---------|------------------|------------------|------------------|-----------------|
| BIKTARVY | BRAND | \$ 14,802,989.44 | \$ 12,161,783.76 | \$ 10,450,697.68 | \$ 1,710,786.08 |
| JARDIANCE | BRAND | \$ 14,571,539.42 | \$ 11,523,037.68 | \$ 10,108,795.30 | \$ 1,413,742.67 |
| SKYRIZI | BRAND | \$ 14,016,154.82 | \$ 11,767,047.06 | \$ 11,338,828.51 | \$ 346,833.91 |
| NOVOLOG | BRAND | \$ 13,231,093.83 | \$ 9,954,675.03 | \$ 9,012,971.73 | \$ 892,707.74 |
| ELIQUIS | BRAND | \$ 12,339,974.79 | \$ 9,720,632.25 | \$ 8,147,307.97 | \$ 1,570,270.92 |
| PANTOPRAZOLE SODIUM | GENERIC | \$ 11,561,555.44 | \$ 551,765.79 | \$ 118,653.75 | \$ 433,179.22 |
| VICTOZA | BRAND | \$ 10,105,228.21 | \$ 7,869,962.27 | \$ 7,275,042.48 | \$ 578,602.10 |
| ONDANSETRON | GENERIC | \$ 10,103,534.18 | \$ 392,487.59 | \$ 144,066.36 | \$ 251,239.31 |
| TALTZ | BRAND | \$ 9,947,474.87 | \$ 7,734,506.53 | \$ 7,192,199.48 | \$ 515,574.69 |
| REVLIMID | BRAND | \$ 9,600,293.60 | \$ 7,749,429.58 | \$ 7,561,455.86 | \$ 134,060.86 |
| TRESIBA | BRAND | \$ 9,529,906.84 | \$ 7,414,128.40 | \$ 6,730,681.80 | \$ 676,388.91 |
| GABAPENTIN | GENERIC | \$ 9,196,666.33 | \$ 820,046.51 | \$ 306,023.33 | \$ 514,146.34 |
| SERTRALINE HYDROCHLORIDE | GENERIC | \$ 9,014,097.71 | \$ 805,884.89 | \$ 123,421.08 | \$ 682,449.90 |
| XELJANZ XR | BRAND | \$ 8,905,747.01 | \$ 7,251,731.92 | \$ 6,622,019.22 | \$ 485,593.68 |
| TREMFYA | BRAND | \$ 8,895,868.58 | \$ 7,266,413.00 | \$ 6,803,420.79 | \$ 289,666.45 |

2021 Q1 – Q4 RX Counts by Plan / Product Type

| Plan Type | Plan Description | Product Type | Product Description | RX Count | Charged Per Script | Allowed Per Script | Paid Per Script | Mbr Resp Per Script |
|-----------|------------------|--------------|---------------------|-----------|--------------------|--------------------|-----------------|---------------------|
| 2 | PPO | 1 | Medical/Health | 3,690,352 | \$ 376.39 | \$ 201.02 | \$ 179.02 | \$ 22.11 |
| 7 | QHP | 1 | Medical/Health | 858,928 | \$ 409.05 | \$ 220.12 | \$ 171.41 | \$ 47.21 |
| 4 | POS | 1 | Medical/Health | 462,802 | \$ 301.49 | \$ 161.31 | \$ 145.72 | \$ 15.59 |
| 3 | HMO | 1 | Medical/Health | 37,815 | \$ 535.64 | \$ 302.26 | \$ 273.07 | \$ 30.71 |
| 7 | QHP | 2 | Ancillary Drug | 281 | \$ 482.04 | \$ 247.45 | \$ 226.67 | \$ 20.78 |

2021 Q1 – Q4 PMPM RX Costs

| Age Group | Member Months | Allowed | Average PMPM |
|-----------|---------------|-------------------|--------------|
| Age <= 14 | 887,160 | \$ 49,711,445.68 | \$ 56.03 |
| Age 15-24 | 806,912 | \$ 80,373,321.35 | \$ 99.61 |
| Age 25-44 | 1,851,005 | \$ 287,459,539.24 | \$ 155.30 |
| Age 45-64 | 1,948,036 | \$ 526,501,949.11 | \$ 270.27 |

Average Allowed Charge PMPM by Age Group

